{"id":"atripla","rwe":[],"tags":[],"trials":[],"_chembl":{"chemblId":"CHEMBL223228","moleculeType":"Small molecule","molecularWeight":"315.68"},"aliases":["EFV/TDF/FTC 600/200/300mg Oral Tablet","tenofovir = Viread®","emtricitabine = Emtriva® (formerly Coviracil)","tenofovir + emtricitabine = Truvada®","efavirenz = Sustiva® and Stocrin®"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"076da359-b3d0-44f7-8c0e-662f5b7a8668","title":"ATRIPLA (EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [DOH CENTRAL PHARMACY]"},"ecosystem":[],"_scrapedAt":"2026-03-27T23:42:46.361Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01778413","phase":"PHASE4","title":"Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine","status":"COMPLETED","sponsor":"Anna Cruceta","startDate":"2013-06-03","conditions":"HIV","enrollment":61},{"nctId":"NCT02652260","phase":"PHASE2","title":"Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-03-04","conditions":"HIV-1, Central Nervous System","enrollment":86},{"nctId":"NCT02403674","phase":"PHASE3","title":"Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-05","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":734},{"nctId":"NCT01380080","phase":"PHASE4","title":"REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-10","conditions":"HIV Infection","enrollment":851},{"nctId":"NCT02722421","phase":"PHASE2","title":"Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-04-06","conditions":"HIV, Contraception","enrollment":28},{"nctId":"NCT03502005","phase":"PHASE4","title":"Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1","status":"COMPLETED","sponsor":"Midland Research Group, Inc.","startDate":"2018-03-01","conditions":"Human Immunodeficiency Virus","enrollment":100},{"nctId":"NCT01006005","phase":"","title":"Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2007-07","conditions":"HIV Infections, Adherence","enrollment":51},{"nctId":"NCT01789879","phase":"PHASE2","title":"A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2014-03-04","conditions":"HIV, Contraception","enrollment":60},{"nctId":"NCT00775606","phase":"PHASE4","title":"Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2008-10","conditions":"Acquired Immune Deficiency Syndrome","enrollment":15},{"nctId":"NCT03122262","phase":"PHASE3","title":"ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2017-01-16","conditions":"HIV-1 Infection","enrollment":1110},{"nctId":"NCT03532425","phase":"PHASE4","title":"B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2018-10-29","conditions":"HIV-1-infection","enrollment":28},{"nctId":"NCT03048422","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-01-19","conditions":"HIV Infections","enrollment":643},{"nctId":"NCT01815580","phase":"PHASE4","title":"HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-07","conditions":"HIV","enrollment":225},{"nctId":"NCT04424264","phase":"PHASE1","title":"The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2019-12-05","conditions":"HIV-1-infection, Tuberculosis","enrollment":18},{"nctId":"NCT01435018","phase":"PHASE3","title":"Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-10-01","conditions":"HIV-1 Infection","enrollment":334},{"nctId":"NCT00344760","phase":"PHASE4","title":"A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2005-01","conditions":"HIV Infections","enrollment":2},{"nctId":"NCT01815736","phase":"PHASE3","title":"Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-27","conditions":"HIV, HIV Infections","enrollment":1443},{"nctId":"NCT02057796","phase":"PHASE4","title":"Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-09","conditions":"HIV-1 Infection","enrollment":1050},{"nctId":"NCT00752856","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-08-26","conditions":"HIV Infections","enrollment":51},{"nctId":"NCT03595709","phase":"PHASE3","title":"Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan","status":"COMPLETED","sponsor":"Yu-Jay Corp.","startDate":"2018-12-06","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT02345226","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-26","conditions":"HIV-1 Infection","enrollment":881},{"nctId":"NCT01352117","phase":"PHASE3","title":"Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-11-18","conditions":"HIV-1 Infection, Kaposi's Sarcoma","enrollment":192},{"nctId":"NCT01403051","phase":"PHASE2","title":"High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-09","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02042001","phase":"PHASE4","title":"Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects","status":"COMPLETED","sponsor":"Azienda Ospedaliera San Gerardo di Monza","startDate":"2015-07-01","conditions":"Impaired Cognition, Depression/Anxiety, Poor Quality Sleep","enrollment":74},{"nctId":"NCT01263015","phase":"PHASE3","title":"A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-02-01","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":844},{"nctId":"NCT02246998","phase":"PHASE4","title":"Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-15","conditions":"HIV-1 Infection","enrollment":72},{"nctId":"NCT01935830","phase":"EARLY_PHASE1","title":"LAAM-HAART PET Imaging","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-08","conditions":"Healthy Volunteers","enrollment":10},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40},{"nctId":"NCT02308332","phase":"PHASE4","title":"Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2015-02","conditions":"Neurocognitive Decline, HIV Associated Neurocognitive Disorder","enrollment":58},{"nctId":"NCT03309566","phase":"PHASE4","title":"Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir","status":"COMPLETED","sponsor":"Laboratorio Elea Phoenix S.A.","startDate":"2016-09-04","conditions":"Healthy","enrollment":24},{"nctId":"NCT00846599","phase":"","title":"Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV-infected Men","status":"COMPLETED","sponsor":"Tufts University","startDate":"2008-01","conditions":"HIV Infection, Cardiovascular Risk, HIV Infections","enrollment":50},{"nctId":"NCT00414635","phase":"PHASE4","title":"FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2006-08","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT02529059","phase":"PHASE4","title":"SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-11","conditions":"HIV","enrollment":40},{"nctId":"NCT02477527","phase":"PHASE4","title":"Atripla to Stribild Switch Study to Evaluate Sleep Disturbances","status":"COMPLETED","sponsor":"Midtown Medical Center, Tampa, FL","startDate":"2015-02","conditions":"HIV, AIDS, Sleep Disorders","enrollment":21},{"nctId":"NCT01929759","phase":"NA","title":"Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-01","conditions":"HIV Disease","enrollment":10},{"nctId":"NCT01978743","phase":"NA","title":"Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-01","conditions":"HIV, HIV-associated Neurocognitive Disorder, Neurotoxicity","enrollment":10},{"nctId":"NCT01701882","phase":"PHASE3","title":"A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2012-09","conditions":"HIV","enrollment":40},{"nctId":"NCT02832778","phase":"PHASE1","title":"Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid","status":"UNKNOWN","sponsor":"St Stephens Aids Trust","startDate":"2016-11-21","conditions":"HIV","enrollment":35},{"nctId":"NCT02547844","phase":"PHASE4","title":"Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-09","conditions":"HIV-1","enrollment":30},{"nctId":"NCT01173510","phase":"PHASE4","title":"A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells","status":"WITHDRAWN","sponsor":"Community Research Initiative of New England","startDate":"2010-08-23","conditions":"HIV Infections, Acquired Immune Deficiency Syndrome","enrollment":""},{"nctId":"NCT02447016","phase":"PHASE4","title":"Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera","status":"TERMINATED","sponsor":"Sheba Medical Center","startDate":"2015-05","conditions":"HIV","enrollment":25},{"nctId":"NCT01509508","phase":"NA","title":"Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2012-03","conditions":"HIV Infection","enrollment":28153},{"nctId":"NCT02283060","phase":"PHASE4","title":"Sleep and Cognition After Atripla to Stribild Switch","status":"UNKNOWN","sponsor":"University of Hawaii","startDate":"2014-09","conditions":"HIV","enrollment":30},{"nctId":"NCT01515813","phase":"PHASE2","title":"Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation","status":"WITHDRAWN","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-11","conditions":"HIV-1 Infection","enrollment":""},{"nctId":"NCT01322932","phase":"","title":"Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey","status":"COMPLETED","sponsor":"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland","startDate":"2010-07","conditions":"HIV Infection","enrollment":95},{"nctId":"NCT01095796","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03","conditions":"HIV, HIV Infections","enrollment":707},{"nctId":"NCT00863668","phase":"NA","title":"Raltegravir Activity In Lymphoid Tissues","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2009-03","conditions":"HIV Infection, HIV Infections","enrollment":""},{"nctId":"NCT00984152","phase":"PHASE3","title":"Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2011-06","conditions":"HIV-1 Infections","enrollment":""},{"nctId":"NCT00785967","phase":"PHASE3","title":"Immune Responses in Patients Treated With Raltegravir","status":"WITHDRAWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2009-01","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT01583439","phase":"NA","title":"The Mochudi Prevention Project ART Protocol","status":"TERMINATED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2012-09","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT01690403","phase":"PHASE1","title":"Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-12","conditions":"Tuberculosis","enrollment":25},{"nctId":"NCT01309243","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-02","conditions":"HIV-1 Infection","enrollment":799},{"nctId":"NCT01180075","phase":"","title":"Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-05","conditions":"Human Immunodeficiency Virus","enrollment":85},{"nctId":"NCT01195467","phase":"PHASE3","title":"Atripla to Raltegravir Switch Study for CNS Toxicity","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2010-10","conditions":"HIV Infection","enrollment":40},{"nctId":"NCT01694017","phase":"PHASE4","title":"Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy","status":"COMPLETED","sponsor":"Tufts University","startDate":"2012-11","conditions":"HIV","enrollment":68},{"nctId":"NCT02285374","phase":"PHASE4","title":"Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity","status":"UNKNOWN","sponsor":"St Stephens Aids Trust","startDate":"2014-11","conditions":"HIV","enrollment":40},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT00946595","phase":"PHASE2, PHASE3","title":"Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2009-11","conditions":"HIV Infections","enrollment":420},{"nctId":"NCT00869557","phase":"PHASE2","title":"Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2009-04","conditions":"HIV, HIV Infections","enrollment":71},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT01270802","phase":"PHASE4","title":"Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients","status":"COMPLETED","sponsor":"Indiana University","startDate":"2011-04","conditions":"HIV","enrollment":30},{"nctId":"NCT01286740","phase":"PHASE2","title":"Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-01","conditions":"HIV-1 Infection","enrollment":50},{"nctId":"NCT00862823","phase":"PHASE4","title":"The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2009-02","conditions":"Healthy","enrollment":14},{"nctId":"NCT00573001","phase":"PHASE3","title":"Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2008-07","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00936195","phase":"PHASE3","title":"Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial","status":"WITHDRAWN","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2010-01","conditions":"HIV Infection, Pregnancy, Breastfeeding","enrollment":""},{"nctId":"NCT00615745","phase":"PHASE4","title":"ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-04","conditions":"HIV Infections","enrollment":115},{"nctId":"NCT01343225","phase":"PHASE4","title":"Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection","status":"UNKNOWN","sponsor":"East Carolina University","startDate":"2011-05","conditions":"HIV","enrollment":40},{"nctId":"NCT01108926","phase":"PHASE1","title":"PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2010-06","conditions":"HIV Infection, HIV Infections","enrollment":19},{"nctId":"NCT00112047","phase":"PHASE3","title":"Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-07","conditions":"HIV Infections","enrollment":517},{"nctId":"NCT00615810","phase":"PHASE4","title":"ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-03","conditions":"HIV Infections","enrollment":159}],"_emaApprovals":[],"_faersSignals":[{"count":9587,"reaction":"BONE DENSITY DECREASED"},{"count":5891,"reaction":"CHRONIC KIDNEY DISEASE"},{"count":4963,"reaction":"TOOTH LOSS"},{"count":4746,"reaction":"RENAL INJURY"},{"count":4617,"reaction":"RENAL FAILURE"},{"count":4508,"reaction":"BONE LOSS"},{"count":4359,"reaction":"OSTEONECROSIS"},{"count":4309,"reaction":"PAIN"},{"count":4275,"reaction":"SKELETAL INJURY"},{"count":4264,"reaction":"EMOTIONAL DISTRESS"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":84,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Atripla","genericName":"Atripla","companyName":"Professor Francois Venter","companyId":"professor-francois-venter","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":3},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}